COMPASS Pathways plc reports biotechnology developments centered on COMP360, its proprietary synthetic psilocybin treatment candidate for serious mental health conditions, with treatment-resistant depression as the primary disclosed focus. News commonly covers clinical data, FDA and UK regulatory designations, NDA submission and review activity, and the company's work on delivery models for psychedelic treatment in clinical settings.
Recurring updates also include financial results and business highlights, investor conference participation, collaborations with psychiatry and care-delivery organizations, healthcare provider training initiatives, and equity compensation actions under Nasdaq rules. As an ADR-listed issuer, CMPS news can reflect parent-company operating updates and American Depositary Share-related corporate actions.
Compass Pathways (CMPS) granted equity awards to one senior leader and ten newly hired non-executive employees as employment inducements.
The senior leader’s September 30, 2026 awards comprised options for 121,800 shares at an exercise price of $12.44 and restricted share units covering 58,000 shares. The October 1, 2026 employee awards comprised options for 97,100 shares at $11.95 and restricted share units, or nominal cost options for UK employees, covering 46,200 shares.
The awards vest over four years, subject to continued employment. The board’s Compensation and Leadership Development Committee approved the grants under the 2026 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Compass Pathways (Nasdaq: CMPS) appointed Kelley Boucher as Chief People Officer, effective September 30, 2026, to oversee its people strategy.
Her initial focus will be guiding the company’s planned evolution toward launching COMP360 psilocybin. Compass plans a launch in the first half of 2027, subject to FDA approval, and is preparing to submit its new drug application in the fourth quarter of 2026. Boucher previously served as Chief People Officer at Apellis Pharmaceuticals and held human resources leadership roles at Alnylam Pharmaceuticals, Abiomed and Shire.
Compass Pathways (CMPS) will participate in the TD Cowen 6th Annual Novel Mechanisms in Neuropsychiatry Summit on September 23, 2026, including a fireside chat at 1:00pm ET.
A live audio webcast of the fireside chat will be available via an online link, with a replay accessible for 30 days on the Investors “Events” page of the Compass website. Compass is developing its proprietary investigational COMP360 psilocybin for treatment-resistant depression and post-traumatic stress disorder and holds Breakthrough Therapy designation from the US FDA and ILAP designation in the UK for TRD.
Compass Pathways (CMPS) launched Change the Tune in TRD, a new U.S. disease education initiative for healthcare providers focused on treatment-resistant depression (TRD), timed with its debut at Psych Congress 2026.
The campaign explores the neurobiology of TRD and care pathways, highlighting that TRD arises from major depressive disorder but is marked by longer and more persistent episodes and resistance to standard treatments. Referencing published data, Compass notes that compared to MDD, patients with TRD experience almost three times longer depressive episodes, remission rates of about 13% versus 42%, and relapse rates of 53% versus 31%. The program uses digital resources, key opinion leader perspectives, and a dedicated website to support earlier and more consistent identification of TRD and encourage clinicians to recognize TRD-specific patterns.
At Psych Congress 2026, the initiative will be presented in a three-panel Innovation Theater addressing evolving neurobiology, the burden of multiple antidepressant trials, impacts of repeated treatment failure, and building effective care networks.
Compass Pathways (CMPS)/b) awarded Strata Mental Health Solutions one of five U.S. healthcare provider training grants to build U.S. provider training programs for COMP360, its investigational psilocybin treatment, if approved.Strata’s team helped develop the original COMP360 clinical trial training and will base the new curriculum on the trial delivery model, using clinical faculty with direct COMP360 experience. Compass has reported positive results from two Phase 3 trials of COMP360, with a rolling NDA submission expected to be completed in Q4 2026 and a potential commercial launch anticipated in the first half of 2027. The grant-funded program will include structured training and certification, site-readiness consulting, and ongoing clinical support for multidisciplinary teams.
Compass Pathways (CMPS) selected Fluence on September 10, 2026 to develop a post-approval U.S. healthcare provider training program for COMP360 psilocybin treatment, if the therapy receives FDA approval. The new Post-Approval COMP360 Psilocybin Certificate Program will prepare clinicians to support patients through the COMP360 treatment experience for treatment-resistant depression.
The curriculum will progress through three modules: Foundations of Psychedelic Care, Understanding Psilocybin, and COMP360 Certification. It will cover psychedelic care fundamentals, psilocybin science, and COMP360-specific topics including regulations, patient preparation, treatment administration, and follow-up. Fluence was chosen via a competitive process based on its psychedelic training expertise, scalability, and regulatory alignment.
Compass Pathways (CMPS) has awarded U.S. healthcare provider training grants to five organizations to support post-approval delivery of its investigational COMP360 psilocybin treatment for treatment-resistant depression (TRD), if approved.
The competitive process initially planned for three awardees but expanded to five: CME Outfitters, Emory University, Fluence International, Integrative Psychiatry Institute, and Strata Mental Health Solutions. These organizations will independently design and deliver scalable, high-quality psychedelic training programs, retaining full control over content, faculty, and educational design in line with ACCME independence standards, while Compass provides funding and recognition as grant awardees.
The grant program aims to build foundational psychedelic training and structured COMP360-specific education to support operational readiness at sites of care following an expected U.S. commercial launch, if approved. Compass has separately developed real-world delivery and training guidance documents that HCPs can request via a dedicated U.S. medical information email.
Compass Pathways (CMPS) will participate in three investor conferences in New York during the week of September 14, 2026.
Management is scheduled for fireside chats at the H.C. Wainwright Annual Global Investment Conference at 3:30pm ET on September 15, the Morgan Stanley 24th Annual Global Healthcare Conference at 11:30am ET on September 16, and Deutsche Bank’s 2026 Healthcare Summit at 11:00am ET on September 17.
A live audio webcast of each fireside chat, and a 30-day replay, will be available via the Events page in the Investors section of the Compass Pathways website.
Compass Pathways (CMPS) reported new 52‑week topline open‑label Part C data from its Phase 3 COMP005 trial of COMP360 psilocybin in treatment‑resistant depression.
Participants originally randomized to the 25 mg arm who received an additional 25 mg dose in Part C achieved an average 13‑point MADRS reduction from baseline at Week 52, extending durability of effect out to one year. Prior placebo‑arm participants who received their first 25 mg dose in Part C showed a meaningful 10‑point average MADRS reduction by the end of Part C, supporting rapid and durable effects from a single dose. Across all Part C participants who received 25 mg, 40%–45% met response criteria and approximately 30% achieved remission at all timepoints through six weeks post‑dose. The safety profile remained generally well tolerated with no new safety findings. A rolling NDA submission is underway, with final submission expected in Q4 and a potential U.S. launch in the first half of 2027, subject to FDA approval.
Compass Pathways (CMPS) will participate in Psych Congress 2026 in New Orleans from September 14-19, debuting its new U.S. HCP education campaign, Change the Tune in TRD, focused on treatment-resistant depression (TRD).
The campaign will launch in a three‑panel Innovation Theater session on September 15 from 12:15–1:30pm in Room 220-222, featuring Saundra Jain, Bryan B. Shapiro, and Sandhya Prashad. Compass will also present seven poster sessions, including new health economics and outcomes research (HEOR) data on TRD and encore analyses from its COMP360 psilocybin Phase 3 clinical program. Company activities include a disease state booth (#901) and a medical booth (#937).